Andra AP fonden Sells 18,100 Shares of DaVita Inc. (NYSE:DVA)

Andra AP fonden lowered its holdings in DaVita Inc. (NYSE:DVA) by 8.9% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 185,900 shares of the company’s stock after selling 18,100 shares during the period. Andra AP fonden owned approximately 0.23% of DaVita worth $27,801,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of DVA. FMR LLC boosted its holdings in DaVita by 659.9% in the 3rd quarter. FMR LLC now owns 177,406 shares of the company’s stock valued at $29,082,000 after purchasing an additional 154,061 shares during the period. Glenmede Trust Co. NA raised its position in shares of DaVita by 731.6% in the 3rd quarter. Glenmede Trust Co. NA now owns 123,269 shares of the company’s stock valued at $20,207,000 after buying an additional 108,446 shares in the last quarter. JPMorgan Chase & Co. raised its position in shares of DaVita by 17.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 609,076 shares of the company’s stock valued at $99,846,000 after buying an additional 92,014 shares in the last quarter. KBC Group NV raised its position in shares of DaVita by 27.3% in the 3rd quarter. KBC Group NV now owns 313,519 shares of the company’s stock valued at $51,395,000 after buying an additional 67,250 shares in the last quarter. Finally, Strategic Financial Concepts LLC acquired a new position in shares of DaVita in the 4th quarter valued at approximately $9,371,000. Institutional investors own 90.12% of the company’s stock.

DaVita Price Performance

DVA stock opened at $140.27 on Friday. The company has a 50 day simple moving average of $159.89 and a 200 day simple moving average of $157.99. The stock has a market cap of $11.22 billion, a price-to-earnings ratio of 13.06, a P/E/G ratio of 1.07 and a beta of 0.99. DaVita Inc. has a 1 year low of $125.64 and a 1 year high of $179.60. The company has a debt-to-equity ratio of 23.18, a current ratio of 1.26 and a quick ratio of 1.21.

DaVita (NYSE:DVA) last released its quarterly earnings data on Thursday, February 13th. The company reported $2.24 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.14 by $0.10. DaVita had a net margin of 7.31% and a return on equity of 115.48%. Research analysts anticipate that DaVita Inc. will post 10.76 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on DVA shares. Barclays boosted their target price on shares of DaVita from $164.00 to $169.00 and gave the company an “equal weight” rating in a research report on Tuesday, February 18th. Sanford C. Bernstein set a $184.00 target price on shares of DaVita in a research report on Friday, February 21st. Finally, Cowen restated a “hold” rating on shares of DaVita in a research report on Tuesday, February 18th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and two have given a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $166.33.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.